1. Home
  2. Clinical Topics
  3. FDA approves Synribo for chronic myelogenous leukemia
Clinical TopicsDrugs and DevicesHealthcare & TechnologyNewsOncologyWeb Exclusives

FDA approves Synribo for chronic myelogenous leukemia


On Oct. 26, the U.S. Food and Drug Administration (FDA) approved Synribo (omacetaxine mepesuccinate) for the treatment of adults with chronic myelogenous leukemia. Synribo blocks certain proteins that promote the development of cancerous cells. Read more.

Leave a Reply

Your email address will not be published.

Fill out this field
Fill out this field
Please enter a valid email address.

Get your free subscription to NurseLine!

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts